

In re: Glucksmann *et al.*

Appl. No.: 09/495,823

Filed: January 31, 2000

Page 2

_____, _____, or _____, or a complement thereof;

c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit Numbers _____, _____, _____, or _____;

d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit Numbers _____, _____, _____, or _____, wherein the fragment comprises at least 12 contiguous amino acids of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit Numbers _____, _____, _____, or _____; and

e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit Numbers _____, _____, _____, or _____, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:2, 4, 6, or 8, or a complement thereof under stringent conditions.

244. The isolated nucleic acid molecule of claim 243, which is selected from the group consisting of:

a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2, 4, 6, or 8, the cDNA insert of any one the plasmids deposited with ATCC as Patent Deposit Numbers _____, _____, _____, or _____, or a complement thereof; and

RTA01/2077334v1

In re: Glucksmann *et al.*
Appl. No.: 09/495,823
Filed: January 31, 2000
Page 3

b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit Numbers _____, _____, _____, or _____.

245. The nucleic acid molecule of claim 243 further comprising vector nucleic acid sequences.

a1
Cured
246. The nucleic acid molecule of claim 243 further comprising nucleic acid sequences encoding a heterologous polypeptide.

247. A host cell which contains the nucleic acid molecule of claim 243.

248. The host cell of claim 247 which is a mammalian host cell.

249. A nonhuman mammalian host cell containing the nucleic acid molecule of claim 243.

250. An isolated polypeptide selected from the group consisting of:

a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit Numbers _____, _____, _____, or _____, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit Numbers _____, _____, _____, or _____;

In re: Glucksmann *et al.*
Appl. No.: 09/495,823
Filed: January 31, 2000
Page 4

- A1
Catal
- b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit Numbers _____, _____, _____, or _____, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:2, 4, 6, or 8, or a complement thereof under stringent conditions; and
- c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:2, 4, 6, or 8, or a complement thereof.

251. The isolated polypeptide of claim 250 comprising the amino acid sequence of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit Numbers _____, _____, _____, or _____.

252. The polypeptide of claim 250 further comprising heterologous amino acid sequences.

253. An antibody which selectively binds to a polypeptide of claim 250.

254. A method for producing a polypeptide selected from the group consisting of:
- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit Numbers _____, _____, _____, or _____;
- b) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit Numbers _____,

In re: Glucksmann *et al.*
Appl. No.: 09/495,823
Filed: January 31, 2000
Page 5

_____, _____, or _____, wherein the fragment comprises at least 12 contiguous amino acids of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit Numbers _____, _____, _____, or _____; and

c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:1, 3, 5, or 7, or an amino acid sequence encoded by the cDNA insert of any of the plasmids deposited with ATCC as Patent Deposit Numbers _____, _____, _____, or _____, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:2, 4, 6, or 8, or a complement thereof under stringent conditions; comprising culturing the host cell of claim 247 under conditions in which the nucleic acid molecule is expressed.

A,
Cured

255. The method of claim 252 wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:1, 3, 5, or 7.

256. A method for detecting the presence of a polypeptide of claim 250 in a sample, comprising:

- a) contacting the sample with a compound which selectively binds to a polypeptide of claim 250; and
- b) determining whether the compound binds to the polypeptide in the sample.

257. The method of claim 256, wherein the compound which binds to the polypeptide is an antibody.

258. A kit comprising a compound which selectively binds to a polypeptide of claim 250 and instructions for use.

In re: Glucksmann *et al.*

Appl. No.: 09/495,823

Filed: January 31, 2000

Page 6

259. A method for detecting the presence of a nucleic acid molecule of claim 243 in a sample, comprising the steps of:

- AI
Cancel
- a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
 - b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.

260. The method of claim 259, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.

261. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 243 and instructions for use.

262. A method for identifying a compound which binds to a polypeptide of claim 250 comprising the steps of:

- a) contacting a polypeptide, or a cell expressing a polypeptide of claim 250 with a test compound; and
- b) determining whether the polypeptide binds to the test compound.

263. The method of claim 262, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

- a) detection of binding by direct detecting of test compound/polypeptide binding;
- b) detection of binding using a competition binding assay;
- c) detection of binding using an assay for GPCR-like-mediated signal transduction.

In re: Glucksmann *et al.*

Appl. No.: 09/495,823

Filed: January 31, 2000

Page 7

264. A method for modulating the activity of a polypeptide of claim 250 comprising contacting a polypeptide or a cell expressing a polypeptide of claim 250 with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

265. A method for identifying a compound which modulates the activity of a polypeptide of claim 250, comprising:

- A/
Curo
- a) contacting a polypeptide of claim 250 with a test compound; and
 - b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

266. A method for identifying an agent that modulates the level of expression of a nucleic acid molecule of claim 243 in a cell, said method comprising contacting said agent with the cell expressing said nucleic acid molecule such that said level of expression of said nucleic acid molecule can be modulated in said cell by said agent and measuring said level of expression of said nucleic acid molecule.

267. A method for modulating the level of expression of a nucleic acid molecule of claim 243, said method comprising contacting said nucleic acid molecule with an agent under conditions that allow the agent to modulate the level of expression of the nucleic acid molecule.

268. A pharmaceutical composition containing any of the polypeptides in claim 250 in a pharmaceutically acceptable carrier.--